Filing Flows

Filing Flows › HeartSciences (HSCS) › Takeover & LBO

Is HeartSciences (HSCS) a takeover target?

A leveraged buyout does not work for HeartSciences on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-06): As previously disclosed, HeartSciences Inc., a Texas corporation (“ HeartSciences ” or the “ Company ”), entered into an Agreement and Plan of Merger, dated as of June 23, 2026 (as amended on July 27, 2026, the “ Merger Agreement ”), by and.

Why a leveraged buyout does not fit

The buyout model needs HeartSciences' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.

What a takeover could cost

Takeovers in its sector paid a median premium of 14.9% over the share price before the deal (the middle half 9.5% to 33.6%), according to the 17 merger proxies and tender-offer responses on EDGAR that state a premium.

Rumors and deal signals

HeartSciences' latest quarter

HeartSciences, Q1 FY27: revenue $2K (+10% year over year), net loss $3.2M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.

Questions

Is HeartSciences being acquired?

The latest signal on file is from 2026-11-06: As previously disclosed, HeartSciences Inc., a Texas corporation (“ HeartSciences ” or the “ Company ”), entered into an Agreement and Plan of Merger, dated as of June 23, 2026 (as amended on July 27, 2026, the “ Merger Agreement ”), by and. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.

Could private equity buy HeartSciences?

A leveraged buyout does not work for HeartSciences on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.